Pull up NMTC on your screen now

Tiny stock with BIG catalysts                                                                                                                                                                                                                                                                                                                                                                                                                 May 07, 2024 | [Read Online]( Pull up NMTC on your screen now Tiny stock with BIG catalysts 📈 Join us for LIVE TRADING action all day long in the 📈  [Market Master’s trading room]( Now, at absolutely no cost to our readers ✅[Just one click](, and you’re in! Good morning, Jeff Bishop here again! The markets have been powering higher, and I have had a good read on the current trend. Besides some big wins with my paid services, some of the recent stocks I shared with everyone have done extremely well. Just last week, I shared my thoughts on a small biotech stock that has been one of the best performers of the year. I said that it was looking primed for a move, and it made a 20% move higher by the next day. In fact, today, it is touching its 52-week high. On Friday last week, I had a “technical alert” on a small commodities company that was lighting up with chatter from traders.  That stock went on to move nearly 40% higher in just the opening hour of trading and is still grinding higher. While trading isn’t easy right now, I have continued to find winning ideas. And today, I have another big play for you to look at. Pull up NeuroOne Medical (NMTC) on your platform right now. This is a sleepy little stock that has a tendency to spring back to life and make fast moves. I’ve mentioned it a few times in the past, and if you recall, we’ve seen some very nice trades from it.  It’s all about waiting for the right signals, and we just got one of my favorites – a new “GO” trend on the hourly chart (see below): 📈Levels to watch: On the downside, I would keep a close on the support level around $1.12, which NMTC has bounced off of several times in the last couple of weeks. I definitely don’t want to see that broken. On the upside, I think that $1.24 is the first important target, since that was the recent high that was rejected a couple of days ago. If NMTC can trade above that, then the next level to watch is $1.35, which is where the stock started to hit resistance last month. After $1.35, things could really heat up. If the stock starts to trade above that, I’ll update what I see on a technical level. On top of the “GO” signal that was recently fired, there are some other great catalysts that could drive NMTC right now. Insider buying is a big driver of future prices, and yesterday, [this news]( came out… I always say that insiders can sell for a lot of reasons… they only buy for one – they think it is going higher. When I am in doubt about what to do with a stock, I will often follow the strongest insider buying patterns (and there are not many of them right now!). The next thing you should look at is the fact that NMTC is “making the rounds” on business TV lately. They are starting to talk to the media about their cutting-edge medical technology now. Here is a [recent clip]( of NMTC talking on Bloomberg… So what does the company do? NMTC is a medical technology developer of electrodes designed to diagnose and treat a variety of neurological conditions, including epilepsy, Parkinson’s disease, and chronic back pain. Despite being a relatively small company, NMTC has received FDA clearance for three of its devices and has forged powerful partnerships with the likes of the Mayo Clinic — the nation’s top-ranked hospital. NMTC’s clinical partnership with the Mayo Clinic began in 2017, and the first commercial human use of one of NMTC’s electrodes was performed at the Mayo Clinic in November 2020. Today, the Mayo Clinic is a shareholder in NMTC and its leading neurologist, Dr. Greg Worrell, chairs the company’s Scientific Advisory Board. [According to the company](, this collaboration with the Mayo Clinic has produced “disruptive next-generation diagnostic electrodes advancing a new era in neuroscience.” The company’s three FDA-cleared devices are: Evo® Cortical Electrode - A device that can “monitor, record and stimulate the surface of the brain for up to 30 days.” It’s up to seven times thinner and eight times lighter than the legacy silicon-based electrodes. These electrodes are designed to cause less trauma to the brain and therefore generate a decreased immune response, which can interfere with electrode readings. Evo® sEEG Electrode - An advanced diagnostic device for seizure detection. It’s designed to be less invasive and to reduce the risk of “plunging” and brain damage. The company says this electrode offers “proven placement accuracy and outstanding signal quality,” allowing doctors to “capture the vital data [they] need to support more confident diagnoses.” OneRF™ Therapeutic Ablation Electrode System - This is a technology that pairs with the sEEG electrodes to provide therapeutic functionality in addition to the diagnostic. Cleared by the FDA in December, this system can create radiofrequency (“RF”) lesions in nervous tissue for use in neurosurgical procedures. NMTC formed a strategic partnership in July 2020 with Zimmer Biomet (NYSE: ZBH, ~$25B market cap) — “a worldwide leader in robotic technology used in minimally invasive neurosurgeries” — to exclusively commercialize and distribute its EVO® diagnostic electrodes. NMTC received a $2 million upfront payment through this partnership and a $3.5 million accelerated payment for reaching an agreed-upon milestone. For its OneRF™ system, NMTC [announced]( a limited commercial launch on March 26, with CEO David Rosa [appearing on Fox Business]( on April 3 to discuss the breakthrough, and to reveal that the first human implant would be done at the Mayo Clinic that month. On April 9, we [learned]( that the device was implanted in an epileptic patient, and the next day, David Rosa [was interviewed on Bloomberg TV]( about what a “seismic shift” this was for the company. Now that it has reached the commercialization stage for its electrodes, NMTC’s revenues have climbed significantly, from $171,000 in FY 2022 to $1,952,000 for FY 2023. Bottom line: There are a lot of positive catalysts out there for NMTC right now. On the price chart, I think there is a lot of potential right now. The price level for NMTC right now is something that can’t be ignored. I think it is an excellent candidate, and needs to be on your watchlist right now. To Your Success, Jeff Bishop 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! If you have trouble reading anything in this email, [please visit here](. [tw]( Update your email preferences or unsubscribe [here]( © 2024 Market Navigator 62 Calef Hwy. #233 lee, NH 03861, United States of America